The reason for this study is to compare the effect of the study drug RAY1225 to semaglutide on blood sugar levels in participants with type 2 diabetes.
Have been diagnosed with type 2 diabetes mellitus (T2DM)
Have HbA1c between ≥7.0% and ≤11.5%
Have a body mass index (BMI) ≥20 kilograms per meter squared (kg/m²) at screening
Be of stable weight (±5%) for at least 12 weeks before screening
Have type 1 diabetes mellitus
Presence of severe chronic diabetic complications at screening, including but not limited to: proliferative diabetic retinopathy, diabetic macular edema, and severe non-proliferative diabetic retinopathy requiring acute treatment;
History of diabetic ketoacidosis or hyperosmolar hyperglycemic state within 24 weeks prior to randomization;
Occurrence of a Grade 3 hypoglycemic event within 12 months prior to screening, or ≥3 Grade 2 hypoglycemic events (venous or capillary blood glucose <3.0 mmol/L) within 3 months prior to screening, or presence of hypoglycemia-related symptoms ;
Parallel
RAY1225
DrugAdministered SC
Semaglutide
DrugAdministered SC
Change From Baseline in Hemoglobin A1c (HbA1c) (6 mg and 9 mg)
HbA1c is the glycosylated fraction of hemoglobin A.
Percentage of Participants Achieving an HbA1c Target Value of <7%
Percentage of Participants With HbA1c Target Value of <6.5%
Percentage of Participants With HbA1c Target Value of <5.7%
Mean change in fasting serum glucose
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
